福奇:强生及阿斯利康疫苗最快数周内获美国批准紧急使用
美国国家过敏症和传染病研究所所长福奇刚过去周日(17日)接受传媒访问时称,强生(JNJ.US)及阿斯利康(AZN.US)将发送新冠疫苗数据,并最快数周内获得批准。福奇称,可以想像一周内,最多两周,它们正整合数据,并将向美国食品药品监督管理局(FDA)展示。他续称,那些公司获取数据,交由安全监测委员会审视,判断是否适合开始,把它们整合一起并申请紧急使用授权。
倘有关数据足以反映疫苗安全及有效,将属美国在辉瑞(PFE.US)及Moderna(MRNA.US)疫苗外,第三及第四款寻求紧急授权的疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.